Illumina, Inc. (NASDAQ:ILMN) Position Boosted by APG Asset Management N.V.

APG Asset Management N.V. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,768 shares of the life sciences company’s stock after acquiring an additional 4,949 shares during the quarter. APG Asset Management N.V.’s holdings in Illumina were worth $8,451,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ILMN. Gryphon Financial Partners LLC boosted its stake in Illumina by 22.1% in the 4th quarter. Gryphon Financial Partners LLC now owns 1,807 shares of the life sciences company’s stock worth $252,000 after purchasing an additional 327 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in Illumina by 134.1% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 17,316 shares of the life sciences company’s stock worth $2,411,000 after acquiring an additional 9,918 shares during the last quarter. Stifel Financial Corp lifted its position in Illumina by 6.6% during the 4th quarter. Stifel Financial Corp now owns 52,447 shares of the life sciences company’s stock worth $7,303,000 after buying an additional 3,269 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $333,000. Finally, Scotia Capital Inc. bought a new stake in Illumina during the 4th quarter worth about $2,045,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $130.12 on Monday. The firm has a market cap of $20.73 billion, a price-to-earnings ratio of -15.97 and a beta of 1.15. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $148.19. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The company’s 50 day moving average is $126.36 and its 200 day moving average is $120.26.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the business posted $0.32 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Illumina, Inc. will post 3.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ILMN. UBS Group upped their price objective on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Evercore ISI lowered their price target on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. StockNews.com began coverage on Illumina in a research note on Thursday, August 29th. They issued a “buy” rating for the company. Scotiabank cut their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. Finally, Citigroup upped their price target on Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $152.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.